Biography

Drew Cypher is an associate in Weil’s Antitrust group. His practice focuses on civil antitrust litigation and regulatory approval for mergers and acquisitions. He has worked on matters across a wide range of industries, including pharmaceuticals, agriculture, software/technology, and entertainment.
Drew received his J.D. from the University of Virginia School of Law, where he served as an editor of the Virginia Journal of International Law. He earned his B.A., summa cum laude, in Political Science and a minor in Economics from Grove City College.
Drew’s recent experience includes serving on Weil teams representing:
- Microsoft in its $68.7 billion acquisition of Activision Blizzard, Inc., a leading publisher of popular PC, console and mobile games.
- Pilgrim’s Pride in a series of federal class actions across the country brought by direct and indirect purchasers alleging that major chicken producers reduced output to raise the price of broiler chickens.
- MGM Resorts International on multiple transactions, including its $1.625 billion acquisition of the operations of The Cosmopolitan of Las Vegas from Blackstone, the sale of the operations of The Mirage to Hard Rock International for $1.075 billion, and MGM’s sale of the operations of Gold Strike Tunica for approximately $450 million.
- Michael Foods, Inc. in a federal multidistrict antitrust class action in which purchasers of shell eggs and egg products alleged a conspiracy to control supply and artificially maintain and increase the price of shell eggs and egg products.
- William Hill plc, securing antitrust clearance for its approximate £2.9 billion ($3.7 billion) transaction with Caesars Entertainment, Inc.
- Charles River Laboratories International, Inc., securing antitrust clearance for its $295 million acquisition of Explora Biolabs.
Awards and Recognition, Speaking Engagements, Guides and Resources, Latest Thinking, Firm News & Announcements
Latest Thinking
-
Antitrust under Trump 2.0: Early signs point to aggressive merger enforcement
Blog Post — WorthWeil Antitrust Blog
— By
Jasmine Rosner,
Rob Meyer,
Drew Cypher and
Amita Chauhan
— February 28, 2025
The DOJ’s recent suit against HPE-Juniper and the Agencies’ commitment to the 2023 Merger Guidelines is an early sign that antitrust scrutiny of mergers is will remain a priority in the Trump administration. ...
-
Roll-up, roll-up: What’s next for antitrust scrutiny of serial acquisition strategies?
Blog Post — WorthWeil Antitrust Blog
— By
Megan A. Granger,
Chris Chapman and
Drew Cypher
— February 05, 2025
The FTC announced in the final days of the Biden administration that private equity firm Welsh, Carson, Anderson & Stowe had agreed to a settlement to resolve the FTC’s allegations that it spearheaded its portfolio company’s consolidation of anesthesia clinics in violation of the antitrust laws. But while the Democratic Commissioners portrayed the settlement as a victory for their crusade against serial acquisitions, the Republican Commissioners took issue with their colleagues’ perceived antipathy toward private equity and emphasized that this case is an “ordinary application of the most elementary antitrust principles.” With a Republican now leading the FTC and Republicans soon set to be in the majority, what does this all mean for scrutiny of roll-up strategies going forward? ...